Related Experiment Video
Updated: Oct 12, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
The iminodipropionitrile (IDPN)-induced dyskinetic syndrome: behavioral and biochemical pharmacology
1Columbia University, Department of Neurology, College of Physicians and Surgeons, New York, NY 10032.
Abstract:
Chronic administration of iminodipropionitrile causes a persistent behavioral syndrome which is characterized by lateral and vertical head shakes, random circling, hyperactivity and increased acoustic startle response in rodents. These behavioral abnormalities are similar to those observed after the acute administration of serotonin (5-HT) and dopamine (DA) agonists, and of some peptides including thyrotropin-releasing hormone (TRH) and the enkephalins. The data available so far indicate that the 5-HT system which interacts with some other neurotransmitters such as DA and norepinephrine (NE) in both reciprocal and nonreciprocal ways may be primarily involved in the manifestations of this persistent dyskinetic syndrome. Preliminary evaluation of the peptidergic systems has also revealed possible involvement of opiate peptides in the IDPN-induced dyskinetic phenomena. More studies are needed to assess the role of specific molecular events which may occur at cortical, subcortical, and/or spinal levels to cause this interesting psychomotor syndrome.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Drug Toxicity: Dose-Dependent Reactions

